SHANGHAI – China's biotechs are benefiting from an unprecedented blood transfusion. Experienced executives from global pharma companies, and increasingly even big banks, are taking the leap to startups, leaving stable jobs behind. The incentive? Pay packages with stock options that can be worth tens of millions of dollars.